Greg Thoreson

Greg Thoreson
Dr. Thoreson attended medical school at the University of Texas School of Medicine in San Antonio, TX. Prior to entering medical school, Dr. Thoreson worked at Pfizer's Global Research and Development headquarters, later completing a research fellowship at Stanford University School of Medicine while in medical school in the department of Cardiology. Dr. Thoreson trained in the Urology residency program at UT Southwestern Medical School and has performed hundreds of robotic and endourological procedures. He currently holds a faculty appointment as a Clinical Assistant Professor in the Department of Surgery at Texas A&M Health Science Center College of Medicine. In addition to the management of benign prostatic hyperplasia, localized and advanced prostate cancer, he has a clinical interest in medical device development, clinical trial design, kidney stone treatment and prevention, recurrent urinary tract infections and voiding dysfunction. He has authored numerous papers on these topics and strives to remain at the forefront of research and development. Dr. Thoreson is a Rockwall native but has made Dallas his home since 2010. He enjoys spending time with his family, cycling and traveling.

Languages Spoken:

English

Medical School:

University of Texas Health Science Center San Antonio

Residency:

UT Southwestern

Undergraduate:

University of Texas at Austin

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only